Moderna Inc said on Monday its COVID-19 vaccine generated a strong immune response and was generally well-tolerated in children aged six to 11 years, citing interim data from a study.
The company said it planned to submit the data to US, European and other regulators soon, reports Reuters.
Moderna said the data showed two 50 microgram doses of the vaccine, half the strength of the doses used in the vaccine given to adults, generated virus-neutralizing antibodies in children.
The majority of side effects were mild or moderate in severity, the company said. The most common solicited adverse events were fatigue, headache, fever and injection site pain.